SYGGF

Synairgen plc

SYGGF, USA

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

https://www.synairgen.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SYGGF
stock
SYGGF

Synairgen shares stay tradeable post-delisting, as top investor waives restrictions Proactive Investors

Read more →
SYGGF
stock
SYGGF

Synairgen PLC (AIM:SNG) waves good bye to London’s AIM market Share Talk

Read more →

Showing 2 of 3

Finn Analysis

(Last Updated 2024-12-31)

Health Score

Return on Equity (ROE)

-

Very Low

-56.51 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-45.36 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.25

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Synairgen plc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2021-03-31

EPS Actual

-0.1139

EPS Estimate

0

EPS Difference

-0.1139

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2024-12-31)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(4.5)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(3)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2024-12-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-12-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-12-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.